These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Roles of dopamine receptor subtypes in mediating modulation of T lymphocyte function. Huang Y; Qiu AW; Peng YP; Liu Y; Huang HW; Qiu YH Neuro Endocrinol Lett; 2010; 31(6):782-91. PubMed ID: 21196914 [TBL] [Abstract][Full Text] [Related]
6. Dopamine: pharmacologic and therapeutic aspects. Velasco M; Luchsinger A Am J Ther; 1998 Jan; 5(1):37-43. PubMed ID: 10099036 [TBL] [Abstract][Full Text] [Related]
7. Dopamine receptors--physiological understanding to therapeutic intervention potential. Emilien G; Maloteaux JM; Geurts M; Hoogenberg K; Cragg S Pharmacol Ther; 1999 Nov; 84(2):133-56. PubMed ID: 10596903 [TBL] [Abstract][Full Text] [Related]
8. Antipsychotic drug-induced increases in ventral tegmental area dopamine neuron population activity via activation of the nucleus accumbens-ventral pallidum pathway. Valenti O; Grace AA Int J Neuropsychopharmacol; 2010 Aug; 13(7):845-60. PubMed ID: 19751544 [TBL] [Abstract][Full Text] [Related]
9. The D(3) dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5. Chen PC; Lao CL; Chen JC J Neurochem; 2009 Aug; 110(4):1180-90. PubMed ID: 19522735 [TBL] [Abstract][Full Text] [Related]
10. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease. Mishra A; Singh S; Tiwari V; Bano S; Shukla S Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851 [TBL] [Abstract][Full Text] [Related]
11. T cell addiction: can pathogenic T cells be controlled using dopamine receptors? Bain KA; Milling S Immunology; 2019 Nov; 158(3):151-152. PubMed ID: 31625164 [TBL] [Abstract][Full Text] [Related]
12. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate. Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD Psychopharmacology (Berl); 1995 Feb; 117(4):403-12. PubMed ID: 7604140 [TBL] [Abstract][Full Text] [Related]
13. Are All Dopamine Agonists Essentially the Same? Torti M; Bravi D; Vacca L; Stocchi F Drugs; 2019 May; 79(7):693-703. PubMed ID: 30968290 [TBL] [Abstract][Full Text] [Related]
14. Dopamine and the regulation of cognition and attention. Nieoullon A Prog Neurobiol; 2002 May; 67(1):53-83. PubMed ID: 12126656 [TBL] [Abstract][Full Text] [Related]
16. The physiology, signaling, and pharmacology of dopamine receptors. Beaulieu JM; Gainetdinov RR Pharmacol Rev; 2011 Mar; 63(1):182-217. PubMed ID: 21303898 [TBL] [Abstract][Full Text] [Related]
17. Dopamine receptors modulate T lymphocytes via inhibition of cAMP-CREB signaling pathway. Huang Y; Chen CC; Wang TT; Qiu YH; Peng YP Neuro Endocrinol Lett; 2016 Dec; 37(7):491-500. PubMed ID: 28326743 [TBL] [Abstract][Full Text] [Related]
18. Changes of contrast gain in cat dorsal lateral geniculate nucleus by dopamine receptor agonists. Zhao Y; Kerscher N; Eysel U; Funke K Neuroreport; 2001 Sep; 12(13):2939-45. PubMed ID: 11588607 [TBL] [Abstract][Full Text] [Related]
19. Dopamine and its receptors play a role in the modulation of CCR5 expression in innate immune cells following exposure to Methamphetamine: Implications to HIV infection. Basova L; Najera JA; Bortell N; Wang D; Moya R; Lindsey A; Semenova S; Ellis RJ; Marcondes MCG PLoS One; 2018; 13(6):e0199861. PubMed ID: 29944719 [TBL] [Abstract][Full Text] [Related]
20. Tyrosine hydroxylase, aromatic L-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs. Cho S; Duchemin AM; Neff NH; Hadjiconstantinou M Brain Res; 1999 Jun; 830(2):237-45. PubMed ID: 10366680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]